Atopic Dermatitis
Leo Pharma reveals positive results for its JAK cream in hand eczema, competing with Incyte’s Opzelura
In February, Leo Pharma created a buzz by announcing the success of its JAK-inhibitor cream, delgocitinib, in a phase 3 ...
Incyte launches eczema awareness campaign featuring actor and teen patient on Opzelura
Incyte has introduced a new advertising campaign for Opzelura, featuring the actor and singer Mandy Moore, in an effort to ...
Dermavant plans to file Vtama for FDA approval after positive results in itchy skin condition
Dermavant is advancing in the race to develop nonsteroidal topical treatments for autoimmune skin conditions, building on its FDA approval ...
Eli Lilly Faces Third FDA Rejection in 2023, Eczema Drug Lebrikizumab Denied Approval
Eli Lilly, which had set ambitious plans to introduce four new drugs in 2023, has faced another setback on the ...
Evommune abandons EVO101, a topical IRAK4 inhibitor, for atopic dermatitis
Evommune, a California-based biotech company, has made the strategic decision to discontinue its sole clinical-stage asset, EVO101, following a thorough ...
Almirall uses famous paintings to raise awareness of atopic dermatitis
Almirall, a Barcelona-based pharmaceutical company collaborated with Eli Lilly on the development of the atopic dermatitis drug candidate lebrikizumab, has ...
Apogee Doses First Patients in Phase I Trial of APG777
Source – Apogee Therapeutics Apogee Therapeutics has embarked on a significant milestone by commencing the dosing of healthy volunteers in ...
Promising Phase IIb Results in Atopic Dermatitis: amlitelimab as a Groundbreaking Treatment
Source – Sanofi On June 27, 2023, Sanofi announced positive Phase IIb Results. Amlitelimab shows promise as a first-in-class investigational ...
